The Long-Term Outcomes Following the Application of Intralesional Epidermal Growth Factor in Patients With Diabetic Foot Ulcers

Kahraman, Murat; Mısır, Abdülhamit; Kızkapan, Turan Bilge; Özçamdallı, Mustafa; Uzun, Erdal; Mutlu, Mahmut

doi:10.1053/j.jfas.2018.08.041

Cited by 11 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study by Kahraman et al evaluating long-term results of 34 patients with DFU undergoing intralesional rhEGF, patients received an average of 18 doses of rhEGF (33). In the five-year follow-up, four patients died due to diabetic complications.…”

Section: Discussionmentioning

confidence: 99%

Intralesional epidermal growth factor application is a potential therapeutic strategy to improve diabetic foot ulcer healing and prevent amputation

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Intralesional epidermal growth factor application is a potential therapeutic strategy to improve diabetic foot ulcer healing and prevent amputation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Amputation is sometimes unavoidable for the patients with CDFU. [16][17][18][19] Unfortunately, the mortality rate increases considerably after amputation. 5 Because of this, optimal management of CDFUs and amputation prevention strategies has a vital importance for such patients.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Intralesional Human Epidermal Growth Factor on Wound Healing in Chronic Diabetic Foot Ulcer: A Retrospective Analysis of Patient Results

Gökşin¹,

Çayır²

2022

Turkiye Klinikleri J Dermatol

View full text Add to dashboard Cite

show abstract

“…[18]. В 2019 г. опубликовано первое исследование, в котором сообщалось о долгосрочных результатах применения ЭФР у пациентов с СДС [19]. Наблюдение за 29 пациентами проводилось в течение 5 лет и показало низкую частоту рецидивов раневых дефектов и малых ампутаций, отсутствие высоких ампутаций.…”

Section: Abstract: Diabetes Mellitus; Diabetic Foot Ulcer; Epidermal unclassified

Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus

2021

View full text Add to dashboard Cite

BACKGROUND: Diabetic foot ulcer (DFU) is a dangerous complication of diabetes mellitus (DM), which can lead to the development of chronic wounds and amputations. Recombinant human epidermal growth factor (rhEGF) can be used as an adjuvant treatment for chronic wounds resistant to standard treatment. Studies have demonstrated its clinical efficacy, however, there is insufficient information on the long-term results of treatment, its safety and the effect on the progression of diabetes complications, adverse cardiovascular events and the development of cancer.AIM: To assess the long-term results of rhEGF therapy for trophic foot ulcers in individuals with multiple complications of diabetes.METHODS: The study included 20 patients with type 1 and type 2 diabetes and various forms of DFS without critical ischemia, who had previously been treated with DFS using rhEGF in order to assess the general condition, progression of microand macrovascular complications of diabetes, adverse cardiovascular events, the development of cancer and the quality of life.RESULTS: There was a statistically significant difference between the area of wound defects, the percentage of granulation tissue that filled the wound defect, before the start of rhEGF treatment and at the time of discharge from the hospital (p <0.05). During treatment with rhEGF, mild adverse events were observed in 35%. Complete epithelialization of wounds in most patients occurred in 3 [2; 4] months. In 11.76%, the wound was not completely epithelialized. Relapse occurred in 5.8% due to non-compliance with limb unloading. Minor amputation was performed in 1 patient. Progression of diabetic retinoand nephropathy was revealed in 23.5%. 11.76% suffered myocardial infarction of unknown age, 1 patient (5.88%) suffered acute cerebrovascular accident. Serious adverse events in the form of PE with a fatal outcome and critical ischemia of the lower limb were recorded in 5.8%.CONCLUSIONS: As a result of the study of long-term results of rhEGF treatment of chronic foot wounds, a low percentage of relapses and small amputations, the absence of high amputations and oncological diseases, the development of serious adverse events in 2 patients, the progression of diabetic retinoand nephropathy in 4 patients, the development of IM of unknown age in 2 patients was recorded. and stroke in 1 patient after rhEGF therapy.

show abstract

The Long-Term Outcomes Following the Application of Intralesional Epidermal Growth Factor in Patients With Diabetic Foot Ulcers

Cited by 11 publications

References 34 publications

Intralesional epidermal growth factor application is a potential therapeutic strategy to improve diabetic foot ulcer healing and prevent amputation

Intralesional epidermal growth factor application is a potential therapeutic strategy to improve diabetic foot ulcer healing and prevent amputation

The Effect of Intralesional Human Epidermal Growth Factor on Wound Healing in Chronic Diabetic Foot Ulcer: A Retrospective Analysis of Patient Results

Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus

Contact Info

Product

Resources

About